Closure Ends Federal Civil and Criminal Investigations of the
Medtronic, Inc. (NYSE: MDT) today announced it has been notified by the
U.S. Department of Justice (DOJ) and the Office of the United States
Attorney for the District of Massachusetts that federal prosecutors have
closed their investigation of Medtronic related to INFUSE® Bone Graft.
The status of this federal civil and criminal investigation has been
regularly reported in Medtronic's quarterly disclosures.
"After several years of investigation, we are pleased that the
Department of Justice and the U.S. Attorney's Office have come to the
decision to close their investigation of the company related to INFUSE
Bone Graft," said Chris O'Connell, executive vice president and group
president, Restorative Therapies Group, which includes the company's
Medtronic, Inc. (www.medtronic.com),
headquartered in Minneapolis, is the global leader in medical technology
? alleviating pain, restoring health, and extending life for millions of
people around the world.
Any forward-looking statements are subject to risks and uncertainties
such as those described in Medtronic's periodic reports on file with the
Securities and Exchange Commission. Actual results may differ materially
from anticipated results. Medtronic may be subject to legal actions
regarding the INFUSE Bone Graft or its other products in addition to
those described herein. The outcomes of such legal actions, and the
impact of such legal actions on Medtronic's financial condition and
results of operation, are not within Medtronic's control.